Mean values of observed data, predicted minimum, and predicted maximum values of ST1571 in combination with other anticancer agents
| Combined drug . | Cell line . | No. of data points . | Observed data* . | Predicted minimum† . | Predicted maximum‡ . | Effect . |
|---|---|---|---|---|---|---|
| Recombinant IFN-α | KU812 | 10 | 0.27 | 0.40 | 0.89 | Synergism (P < .01) |
| K562 | — | ND | ND | ND | ||
| TCC-S | 7 | 0.29 | 0.34 | 0.78 | Additive/synergism (N5)2-153 | |
| TCC-Y | 7 | 0.16 | 0.32 | 0.93 | Synergism (P < .02) | |
| Natural IFN-α | KU812 | 13 | 0.32 | 0.44 | 0.84 | Synergism (P < .01) |
| K562 | — | ND | ND | ND | ||
| TCC-S | 7 | 0.17 | 0.24 | 0.80 | Synergism (P < .05)2-153 | |
| TCC-Y | 6 | 0.18 | 0.31 | 0.92 | Synergism (P< .05) | |
| Hydroxyurea | KU812 | 11 | 0.61 | 0.42 | 0.73 | Additive |
| K562 | 11 | 0.64 | 0.47 | 0.82 | Additive | |
| TCC-S | 8 | 0.66 | 0.50 | 0.74 | Additive | |
| TCC-Y | 7 | 0.82 | 0.74 | 0.85 | Additive | |
| Cytarabine | KU812 | 10 | 0.56 | 0.45 | 0.71 | Additive |
| K562 | 9 | 0.45 | 0.37 | 0.87 | Additive | |
| TCC-S | 12 | 0.51 | 0.36 | 0.91 | Additive | |
| TCC-Y | 7 | 0.54 | 0.52 | 0.63 | Additive | |
| Homoharringtonine | KU812 | 10 | 0.58 | 0.52 | 0.71 | Additive |
| K562 | 12 | 0.68 | 0.48 | 0.74 | Additive | |
| TCC-S | 11 | 0.78 | 0.49 | 0.89 | Additive | |
| TCC-Y | 6 | 0.76 | 0.70 | 0.84 | Additive | |
| Doxorubicin | KU812 | 8 | 0.53 | 0.42 | 0.82 | Additive |
| K562 | 12 | 0.55 | 0.38 | 0.94 | Additive | |
| TCC-S | 11 | 0.51 | 0.34 | 0.77 | Additive | |
| TCC-Y | 7 | 0.51 | 0.49 | 0.60 | Additive | |
| Etoposide | KU812 | 9 | 0.62 | 0.48 | 0.75 | Additive |
| K562 | 9 | 0.67 | 0.33 | 0.86 | Additive | |
| TCC-S | 11 | 0.77 | 0.61 | 0.80 | Additive | |
| TCC-Y | 8 | 0.47 | 0.45 | 0.66 | Additive | |
| 4-Hydroperoxy cyclophosphonamide | KU812 | 10 | 0.53 | 0.44 | 0.70 | Additive |
| K562 | 9 | 0.51 | 0.52 | 0.81 | Additive/synergism (NS) | |
| TCC-S | 10 | 0.67 | 0.55 | 0.80 | Additive | |
| TCC-Y | 5 | 0.50 | 0.46 | 0.68 | Additive | |
| Methotrexate | KU812 | 12 | > 1.10 | 0.31 | 0.52 | Antagonism (P < .01) |
| K562 | 12 | 0.83 | 0.33 | 0.82 | Additive/antagonism (P = NS) | |
| TCC-S | 12 | 0.84 | 0.34 | 0.75 | Antagonism (P< .02) | |
| TCC-Y | 7 | > 1.06 | 0.46 | 0.65 | Antagonism (P < .02) | |
| Vincristine | KU812 | 10 | 0.53 | 0.59 | 0.76 | Synergism (P < .02) |
| K562 | 10 | 0.45 | 0.46 | 0.89 | Additive/synergism (P = NS) | |
| TCC-S | 10 | 0.43 | 0.64 | 0.80 | Synergism (P< .05) | |
| TCC-Y | 6 | 0.42 | 0.49 | 0.67 | Synergism (P < .05) |
| Combined drug . | Cell line . | No. of data points . | Observed data* . | Predicted minimum† . | Predicted maximum‡ . | Effect . |
|---|---|---|---|---|---|---|
| Recombinant IFN-α | KU812 | 10 | 0.27 | 0.40 | 0.89 | Synergism (P < .01) |
| K562 | — | ND | ND | ND | ||
| TCC-S | 7 | 0.29 | 0.34 | 0.78 | Additive/synergism (N5)2-153 | |
| TCC-Y | 7 | 0.16 | 0.32 | 0.93 | Synergism (P < .02) | |
| Natural IFN-α | KU812 | 13 | 0.32 | 0.44 | 0.84 | Synergism (P < .01) |
| K562 | — | ND | ND | ND | ||
| TCC-S | 7 | 0.17 | 0.24 | 0.80 | Synergism (P < .05)2-153 | |
| TCC-Y | 6 | 0.18 | 0.31 | 0.92 | Synergism (P< .05) | |
| Hydroxyurea | KU812 | 11 | 0.61 | 0.42 | 0.73 | Additive |
| K562 | 11 | 0.64 | 0.47 | 0.82 | Additive | |
| TCC-S | 8 | 0.66 | 0.50 | 0.74 | Additive | |
| TCC-Y | 7 | 0.82 | 0.74 | 0.85 | Additive | |
| Cytarabine | KU812 | 10 | 0.56 | 0.45 | 0.71 | Additive |
| K562 | 9 | 0.45 | 0.37 | 0.87 | Additive | |
| TCC-S | 12 | 0.51 | 0.36 | 0.91 | Additive | |
| TCC-Y | 7 | 0.54 | 0.52 | 0.63 | Additive | |
| Homoharringtonine | KU812 | 10 | 0.58 | 0.52 | 0.71 | Additive |
| K562 | 12 | 0.68 | 0.48 | 0.74 | Additive | |
| TCC-S | 11 | 0.78 | 0.49 | 0.89 | Additive | |
| TCC-Y | 6 | 0.76 | 0.70 | 0.84 | Additive | |
| Doxorubicin | KU812 | 8 | 0.53 | 0.42 | 0.82 | Additive |
| K562 | 12 | 0.55 | 0.38 | 0.94 | Additive | |
| TCC-S | 11 | 0.51 | 0.34 | 0.77 | Additive | |
| TCC-Y | 7 | 0.51 | 0.49 | 0.60 | Additive | |
| Etoposide | KU812 | 9 | 0.62 | 0.48 | 0.75 | Additive |
| K562 | 9 | 0.67 | 0.33 | 0.86 | Additive | |
| TCC-S | 11 | 0.77 | 0.61 | 0.80 | Additive | |
| TCC-Y | 8 | 0.47 | 0.45 | 0.66 | Additive | |
| 4-Hydroperoxy cyclophosphonamide | KU812 | 10 | 0.53 | 0.44 | 0.70 | Additive |
| K562 | 9 | 0.51 | 0.52 | 0.81 | Additive/synergism (NS) | |
| TCC-S | 10 | 0.67 | 0.55 | 0.80 | Additive | |
| TCC-Y | 5 | 0.50 | 0.46 | 0.68 | Additive | |
| Methotrexate | KU812 | 12 | > 1.10 | 0.31 | 0.52 | Antagonism (P < .01) |
| K562 | 12 | 0.83 | 0.33 | 0.82 | Additive/antagonism (P = NS) | |
| TCC-S | 12 | 0.84 | 0.34 | 0.75 | Antagonism (P< .02) | |
| TCC-Y | 7 | > 1.06 | 0.46 | 0.65 | Antagonism (P < .02) | |
| Vincristine | KU812 | 10 | 0.53 | 0.59 | 0.76 | Synergism (P < .02) |
| K562 | 10 | 0.45 | 0.46 | 0.89 | Additive/synergism (P = NS) | |
| TCC-S | 10 | 0.43 | 0.64 | 0.80 | Synergism (P< .05) | |
| TCC-Y | 6 | 0.42 | 0.49 | 0.67 | Synergism (P < .05) |